Senseonics Holdings: Business Overview, Financials & Competitive Analysis
Senseonics Holdings scores 6/10 on the AskCyborg Cyborg Score (Solid). Senseonics offers differentiated implantable CGM technology in a growing market, but execution risk and competitive pressures require close monitoring of market adoption and clinical performance. Senseonics operates in the high-growth diabetes technology sector with meaningful competitive differentiation via implantable sensor technology. However, the company faces intense competition from well-capitalized rivals.
What is Senseonics Holdings's industry? Senseonics Holdings (senseonics.com) operates in Medical Devices - Continuous Glucose Monitoring (Diabetes Management). AskCyborg classifies Senseonics Holdings under Medical Devices - Continuous Glucose Monitoring (Diabetes Management) in its company registry.
Senseonics Holdings is a medical technology company focused on continuous glucose monitoring (CGM) devices for diabetes management. The company develops and commercializes the Eversense CGM system, which is implanted ...
Cyborg Score thesis
Senseonics offers differentiated implantable CGM technology in a growing market, but execution risk and competitive pressures...
Read the full analyst-debate transcript →Get the Latest Senseonics Holdings Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSenseonics Holdings Overview
Pro stress-test →Senseonics Holdings is a medical technology company focused on continuous glucose monitoring (CGM) devices for diabetes management. The company develops and commercializes the Eversense CGM system, which is implanted under the skin to monitor blood glucose levels in real-time, offering a non-invasive alternative to traditional finger-stick testing.
Strategic Profile
Pro stress-test →Senseonics differentiates through its implantable CGM technology with extended wear duration (180 days), positioning it as a convenient long-term solution in a growing diabetes management market. The company competes against larger players like Dexcom and Abbott while targeting patients and healthcare providers seeking alternative glucose monitoring solutions.
Competitive Landscape
Pro stress-test →Senseonics competes primarily with Dexcom (DexCom, Inc.), which holds the dominant market share in continuous glucose monitoring, and Abbott's FreeStyle Libre system. These competitors benefit from larger scale, established market presence, and significant R&D investment, while Senseonics differentiates through its implantable 180-day sensor technology.
Industry Context
Senseonics Holdings operates in Medical Devices - Continuous Glucose Monitoring (Diabetes Management).
Key facts
Founded: 2010 · Headquarters: Germantown, US